Owkin spins out Waiv with $33M to commercialize oncology AI
Key Questions
What is Waiv and how much funding did it receive?
Waiv, spun out from Owkin, closed a $33M funding round to commercialize AI for oncology precision testing and biomarker prediction, backed by investors including Destra and MSD. The company focuses on advancing AI applications in cancer diagnostics.
What is neuroClues' recent funding achievement?
neuroClues raised €10M in a Series A round to expand its AI neurological biomarkers platform. This funding accelerates one of the fastest clinical rollouts in European neurology.
What are some recent developments in radiology AI tools?
Aiforia received CE-IVD marking for its AI pathology tool, Rivia raised $15M, and Galatea secured $3.2M. Apple's Studio Display XDR also became an FDA-cleared radiology monitor.
What risks persist in radiology AI adoption?
Radiology AI faces challenges including deepfakes, bias, low data quality, and adoption hurdles. Research shows accuracy and advertising influence women's willingness to pay for AI mammography.
What monitoring aspects are key for these AI oncology and radiology developments?
Key areas to monitor include pilots, regulatory approvals, contracts, hires, and co-investments. Other examples include AI systems approved for psychiatric medication prescription.
Waiv closed $33M for AI oncology precision testing/biomarker prediction (Destra/MSD). neuroClues €10M Series A extends med-AI to neuro biomarkers; XPANCEO eye-tracking lenses for neuro; radiology risks (deepfakes/bias/low data quality/adoption) persist with Aiforia CE-IVD, Rivia $15M, Galatea $3.2M. Monitoring: pilots, regulatory, contracts, hires, co-invests.